Vaccine最新文献

{"title":"Vaccination versus antibody screening for measles immunity in health care workers","authors":"Ruby Schieferdecker ,&nbsp;Tanja Menting ,&nbsp;Annette Mankertz ,&nbsp;Sabine Santibanez ,&nbsp;Cosima Zimmermann ,&nbsp;Jürgen K. Rockstroh ,&nbsp;Anna Maria Eis-Hübinger ,&nbsp;Carolynne Schwarze-Zander","doi":"10.1016/j.vaccine.2025.127845","DOIUrl":"10.1016/j.vaccine.2025.127845","url":null,"abstract":"<div><h3>Aim</h3><div>To promote measles protection in community and health care facilities a law (Measles Protection act, MPA) came into force in Germany requiring documentation of two measles vaccinations or evidence of measles seropositivity for healthcare workers (HCW) born after 1970. The German Standing Committee on Vaccination extended this law to a recommendation of two measles, mumps, rubella (MMR) vaccinations.</div><div>Our aim was to evaluate serology-based vaccination strategies for measles and to consider their extension to mumps and rubella.</div></div><div><h3>Subject and methods</h3><div>Between 11/2020–7/2021, MMR serostatus was assessed in 386 HCW attending the Occupational Health Service Department for pre-employment or regular occupational examinations. Sociodemographic and documented vaccination data were collected.</div></div><div><h3>Results</h3><div>Overall, measles IgG seropositivity was 72 %. Measles IgG was found in 77 %, 74 % and 61 % of employees with no, one and two documented measles vaccinations, respectively (<em>p</em> &lt; 0.05). Seropositivity against MMR was detected in 66 % and 58 % with no and one documented measles vaccination, respectively. Considering measles immunity only anti-measles IgG screening prior vaccination saved costs. However, considering MMR seropositivity screening prior vaccination was not cost-effective. Measurement of measles virus neutralizing potency using a quantitative focus reduction neutralization assay to measure measles virus neutralizing potency indicated immunity in persons with two documented measles vaccine doses but negative or equivocal ELISA IgG results.</div></div><div><h3>Conclusion</h3><div>Measles seropositivity was below 75 % among HCW. In individuals with documentation of two measles vaccine doses ELISA tests underestimate protection, thus no serological testing is needed. Considering measles seropositivity in HCW with no or one documented measles vaccination, measles serological screening before vaccination was most cost-effective. However, aiming at MMR immunity, vaccination of HCW without serological screening was most cost-effective and offers important benefits that should not be dismissed.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"66 ","pages":"Article 127845"},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145270455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the predictors for the uptake of Respiratory Syncytial Virus (RSV) vaccine under the immunization programme in India","authors":"Rhythm Hora ,&nbsp;Arindam Ray ,&nbsp;Amrita Kumari ,&nbsp;Mili Dutta ,&nbsp;Rashmi Mehra ,&nbsp;Amanjot Kaur ,&nbsp;Syed F. Quadri ,&nbsp;Seema Singh Koshal ,&nbsp;Shyam Kumar Singh ,&nbsp;Abida Sultana ,&nbsp;Arup Deb Roy","doi":"10.1016/j.vaccine.2025.127827","DOIUrl":"10.1016/j.vaccine.2025.127827","url":null,"abstract":"<div><h3>Introduction</h3><div>Maternal immunization (MI) has evolved over the past decade, protecting both mother and offspring from infectious diseases. In India, only one vaccine, tetanus toxoid (TT)/ tetanus and diphtheria (Td), is available under the Universal Immunization Programme (UIP) for pregnant women. However, the basket of MI can be expanded by introducing additional maternal vaccines such as the Respiratory Syncytial Virus (RSV) vaccine in the immunization schedule. Therefore, the study aims to explore the potential predictors for the uptake of the RSV vaccine under UIP.</div></div><div><h3>Methodology</h3><div>For the study, relevant data was extracted from the National Family Health Survey (NFHS-5) conducted during 2019–21. A cross-sectional sample of women aged 15–49 years who had given birth in the past 5 years was analyzed. Bivariate statistics and logistic regression analysis were employed to assess the predictors for pregnant women's interaction with healthcare workers (HCWs) during 3rd trimester of pregnancy using Stata 17 software. This measure was used as a proxy to gauge the existing maternal health delivery platform for new vaccine introductions, like RSV, administered during the third trimester.</div></div><div><h3>Results</h3><div>Information from 174,483 women was included in the study. Of them, 59.3 % went for four or more antenatal care (ANC) visits, and a significant proportion (83.8 %) received tetanus injections. The number of antenatal care visits and tetanus injections during pregnancy emerged as strong predictors, with higher ANC visit frequencies with increased odds of meeting with healthcare workers (HCWs) during the third trimester of pregnancy. Further, younger age (20–24 years), middle wealth index group, and residence in rural areas were identified as positive predictors while higher levels of education emerged as a negative predictor.</div></div><div><h3>Conclusion</h3><div>The study highlights the importance of ANC visits and tetanus vaccine uptake in engaging pregnant women with HCWs during the third trimester. These factors indicate readiness for potential interventions and suggest leveraging ANC visits for introducing RSV, a new maternal immunization vaccine.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"66 ","pages":"Article 127827"},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145270456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection","authors":"Angelo Roberto Raccagni ,&nbsp;Giulia Morsica ,&nbsp;Pierluigi Reali ,&nbsp;Riccardo Lolatto ,&nbsp;Costanza Bertoni ,&nbsp;Hamid Hasson ,&nbsp;Alessia Siribelli ,&nbsp;Elena Bruzzesi ,&nbsp;Flavia Passini ,&nbsp;Diana Canetti ,&nbsp;Antonella Castagna ,&nbsp;Silvia Nozza","doi":"10.1016/j.vaccine.2025.127825","DOIUrl":"10.1016/j.vaccine.2025.127825","url":null,"abstract":"<div><h3>Background</h3><div>Universal hepatitis B virus (HBV) vaccination was introduced in Italy in 1991. However, the long-term durability of vaccine-induced protection remains under debate, particularly among high-risk groups such as men who have sex with men (MSM) using HIV pre-exposure prophylaxis (PrEP). This study aimed to assess HBV seroprotection and the immune response to a booster vaccine nearly 30 years after infant immunization among MSM-PrEP users.</div></div><div><h3>Setting</h3><div>This retrospective study included Italian MSM using PrEP under 35 years of age in Milan, Italy, between 2017 and 2024.</div></div><div><h3>Methods</h3><div>HBV serological status was determined at the start of PrEP. Participants with HBsAb levels below 10 mIU/mL were offered a booster dose. Statistical analyses were performed to compare demographic and clinical variables according to seroprotection status and booster response.</div></div><div><h3>Results</h3><div>Overall, among 447 MSM using PrEP, 271 (60.6 %) had HBsAb levels ≥10 mIU/mL, while 176 (39.4 %) &lt;10 mIU/mL at the start of PrEP. Seroprotection was more prevalent among older participants (<em>p</em> = 0.014) and those with higher AST levels (<em>p</em> = 0.019). Of the 55/176 participants who received a booster, 38 (69.1 %) developed protective HBsAb levels. Pre-booster HBsAb levels between 2 and 9.9 mIU/mL were associated with a better booster response (<em>p</em> = 0.032).</div></div><div><h3>Conclusions</h3><div>Almost 40 % of MSM using PrEP lacked protective HBsAb three decades after primary HBV vaccination, and around one-third of booster recipients failed to respond. Due to the high-risk nature of this group, systematic HBsAb screening and booster administration are recommended to ensure adequate protection.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"66 ","pages":"Article 127825"},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145270478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The social lives of the SARS-CoV-2 vaccines: A qualitative study of vaccine understandings and decision-making among people of Black ethnicities in London, UK","authors":"Emily Jay Nicholls ,&nbsp;Denis Onyango ,&nbsp;Vladimir Kolodin ,&nbsp;Zoë Ottaway ,&nbsp;Abi Carter ,&nbsp;Lucy Campbell ,&nbsp;Frank Post ,&nbsp;Shema Tariq","doi":"10.1016/j.vaccine.2025.127802","DOIUrl":"10.1016/j.vaccine.2025.127802","url":null,"abstract":"<div><h3>Background</h3><div>In the first two years of the COVID-19 pandemic, people of Black African and Black Caribbean ethnicities were among the groups most likely to acquire COVID-19, and to develop serious infection, but were also the least likely to have received a SARS-CoV-2 vaccine. Our aim was to explore SARS-CoV-2 vaccine understandings and decision-making among people of Black ethnicities in order to understand the complex drivers of vaccination disparities.</div></div><div><h3>Methods</h3><div>We conducted six online and face-to-face focus group discussions with thirty-six participants of Black ethnicities in London, UK. Topic guides were developed with our community partners and covered impact on daily lives, experiences of COVID-19, knowledge and beliefs (including about prevention measures), and healthcare seeking behaviour and perceptions.</div></div><div><h3>Results</h3><div>Participants described how their relationships with SARS-CoV-2 vaccines were entangled with their belonging to religious communities; how painful histories of medical experimentation on Black people had reemerged in the context of concerns regarding vaccine safety; and how present realities of medical racism and global vaccine inequity shaped their understandings of the vaccines.</div></div><div><h3>Conclusion</h3><div>Our account problematises “vaccine hesitancy” and the hegemonic belief that this is a direct consequence of a lack of knowledge or education. Instead, by engaging with “social lives” of the SARS-Cov-2 vaccines, we trace the rich meanings ascribed to vaccination, and complex and active negotiations around vaccination, among participants. Public health practitioners and policymakers should move beyond conceptualising vaccine hesitancy as irrational or ill informed, and instead acknowledge how such decisions are situated within a wider social, historical and political landscape.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"66 ","pages":"Article 127802"},"PeriodicalIF":4.5,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial","authors":"Tsetsegsaikhan Batmunkh ,&nbsp;Eleanor F.G. Neal ,&nbsp;Otgonjargal Amraa ,&nbsp;Nadia Mazarakis ,&nbsp;Bolor Altangerel ,&nbsp;Naranbaatar Avaa ,&nbsp;Lkhagvagaram Batbayar ,&nbsp;Khishigjargal Batsukh ,&nbsp;Kathryn Bright ,&nbsp;Tsogjargal Burentogtokh ,&nbsp;Lien Anh Ha Do ,&nbsp;Gantuya Dorj ,&nbsp;John D. Hart ,&nbsp;Otgonbold Jamiyandorj ,&nbsp;Khulan Javkhlantugs ,&nbsp;Sarantsetseg Jigjidsuren ,&nbsp;Frances Justice ,&nbsp;Shuo Li ,&nbsp;Khaliunaa Mashbaatar ,&nbsp;Kerryn A. Moore ,&nbsp;Kim Mulholland","doi":"10.1016/j.vaccine.2025.127840","DOIUrl":"10.1016/j.vaccine.2025.127840","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia.</div></div><div><h3>Methods</h3><div>In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented. <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> Identifier: <span><span>NCT05265065</span><svg><path></path></svg></span>.</div></div><div><h3>Results</h3><div>Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63–0.96], <em>p</em> = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm <em>n</em> = 12; standard dose arm <em>n</em> = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm <em>n</em> = 112; standard arm <em>n</em> = 116). SAEs (<em>n</em> = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported.</div></div><div><h3>Conclusions</h3><div>15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"66 ","pages":"Article 127840"},"PeriodicalIF":4.5,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145270482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine” [Vaccine 62 (2025) 127558]","authors":"Tarek El Hindi ,&nbsp;Suvaporn Anugulruengkitt ,&nbsp;Keswadee Lapphra ,&nbsp;Kriengsak Limkittikul ,&nbsp;Auchara Tangsathapornpong ,&nbsp;Claudia M. Galindo ,&nbsp;Michael Hellwig ,&nbsp;Nicholas Roubinis ,&nbsp;Ron Schuring ,&nbsp;Shibadas Biswal ,&nbsp;Nicolas Folschweiller","doi":"10.1016/j.vaccine.2025.127785","DOIUrl":"10.1016/j.vaccine.2025.127785","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"65 ","pages":"Article 127785"},"PeriodicalIF":4.5,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145321692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-pandemic questions in vaccination counseling: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines","authors":"Parichehr Shamsrizi ,&nbsp;Sarah Eitze ,&nbsp;Dorothee Heinemeier ,&nbsp;Anne-Sophie Tänzer ,&nbsp;Mirjam Annina Jenny","doi":"10.1016/j.vaccine.2025.127823","DOIUrl":"10.1016/j.vaccine.2025.127823","url":null,"abstract":"<div><h3>Background</h3><div>We examine patients' informational needs regarding novel vaccination decisions, focusing on what information they expect to receive in doctor-patient communication after having lived through a pandemic.</div></div><div><h3>Method</h3><div>In Study 1, <em>n</em> = 842 German participants received information on a fictional disease and vaccination (called dysomeria), including symptoms, disease impact, vaccine efficacy, and potential side effects. They were asked what questions they would ask their doctor in a consultation. In Study 2, we included <em>n</em> = 1127 people over the age of 60. The participants received information about the novel Respiratory Syncytial Virus (RSV) vaccine and then, they were asked the same open-ended question as in Study 1.</div></div><div><h3>Results</h3><div>An inductively developed categorization system from Study 1 proved effective for coding responses in both studies. Participants frequently raised concerns about vaccine safety, side effects, and contraindications—especially in the context of preexisting medical conditions. Questions also focused on efficacy, booster timing, immunization schedules, vaccine types, and disease incidence. Trust in physicians was important, with participants seeking clarity on both medical recommendations and official guidelines.</div></div><div><h3>Conclusions</h3><div>Healthcare providers should adapt communication strategies, focusing on shared decision-making and personalized vaccination decisions including novel and well-known determinants of vaccination decisions.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"66 ","pages":"Article 127823"},"PeriodicalIF":4.5,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand","authors":"Tomoko Hayashi,&nbsp;Shiyin Yao,&nbsp;Fumi Sato-Kaneko,&nbsp;Renna Cozza,&nbsp;Hiroyuki Baba,&nbsp;Jasmine Jin,&nbsp;Ian Mclaughlin,&nbsp;Fernando Gil,&nbsp;Paola Anguiano Quiroz,&nbsp;Nikunj M. Shukla,&nbsp;Michael Chan,&nbsp;Howard B. Cottam,&nbsp;Dennis A. Carson","doi":"10.1016/j.vaccine.2025.127778","DOIUrl":"10.1016/j.vaccine.2025.127778","url":null,"abstract":"<div><h3>Objectives</h3><div>Despite the clinical efficacy of current intramuscular influenza vaccines in reducing the severity of seasonal infection, they exhibit limited induction of mucosal immunity, which is essential for preventing viral transmission. In addition, intranasal vaccination can induce superior mucosal immunity, enhancing clinical efficacy and reducing transmission, and its self-boosting potential may improve coverage in older adults and those with mobility limitations.</div></div><div><h3>Methods</h3><div>We developed Lipo-<strong>1V270</strong>, a liposomal nanoparticle formulation of the synthetic TLR7 agonist <strong>1V270</strong> using 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and cholesterol for mucosal vaccine delivery. In vitro immune stimulation and in vivo immunogenicity were evaluated using intramuscular and intranasal routes in mouse models, including a heterologous prime-boost regimen with inactivated influenza A virus [IIAV, A/California/04/2009 (H1N1)pdm09] adjuvanted monophosphoryl lipid A (MPLA) priming.</div></div><div><h3>Results</h3><div>In vitro analysis showed that Lipo-<strong>1V270</strong> exhibited attenuated innate immune potency compared to unformulated <strong>1V270</strong>. However, in vivo co-administration of Lipo-<strong>1V270</strong> with IIAV significantly enhanced antigen-specific IgG1 and IgG2a responses. Subsequently, intranasal boosting with Lipo-<strong>1V270</strong>, following intramuscular priming with IIAV adjuvanted with MPLA - a component included in FDA-approved vaccines - elicited robust influenza-hemagglutinin (HA)-specific mucosal IgA and IgG responses in nasal wash. This heterologous prime-boost regimen also induced strong splenic T-cell responses and HA-specific IgG and IgA antibodies in nasal wash without causing significant weight loss for 7 days post-boost in immunized mice.</div></div><div><h3>Conclusions</h3><div>Intranasal administration of Lipo-<strong>1V270</strong> in a heterologous prime-boost vaccination regimen effectively enhances mucosal immunity against influenza virus infection, with an acceptable innate immune-mediated adverse effects profile. This strategy may be applicable to vaccines against other respiratory infectious diseases.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"65 ","pages":"Article 127778"},"PeriodicalIF":4.5,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial for the special issue “Vaccines for the vulnerable”","authors":"Asimenia Angelidou ,&nbsp;Nicola Cotugno ,&nbsp;Amy C. Sherman ,&nbsp;Donato Amodio ,&nbsp;Ofer Levy ,&nbsp;Paolo Palma","doi":"10.1016/j.vaccine.2025.127783","DOIUrl":"10.1016/j.vaccine.2025.127783","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"65 ","pages":"Article 127783"},"PeriodicalIF":4.5,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV vaccination among gay, bisexual, and other men who have sex with men aged 27–45 years in the United States is potentially Cost-saving","authors":"Patrick A. Clay ,&nbsp;Lauri E. Markowitz ,&nbsp;Sameer V. Gopalani ,&nbsp;Arden Baxter ,&nbsp;Julia W. Gargano ,&nbsp;Carla L. DeSisto ,&nbsp;Virginia Senkomago ,&nbsp;Donatus U. Ekwueme ,&nbsp;Md Hafizul Islam ,&nbsp;Harrell W. Chesson","doi":"10.1016/j.vaccine.2025.127798","DOIUrl":"10.1016/j.vaccine.2025.127798","url":null,"abstract":"<div><h3>Background</h3><div>The Advisory Committee on Immunization Practices (ACIP) recommends routine human papillomavirus (HPV) vaccination at age 11 or 12 years (vaccination can be given starting at age 9 years), with catch-up vaccination for all persons through age 26 years. ACIP recommends shared clinical decision-making for HPV vaccination of persons aged 27 through 45 years, although modeling indicated that broadly vaccinating persons in this age group would not be cost-effective. To help inform clinical decision-making, the objective of this study was to estimate the cost-effectiveness of HPV vaccination among gay, bisexual, and other men who have sex with men (GBMSM) aged 27 through 45 years in the United States.</div></div><div><h3>Method</h3><div>We used an age-specific, compartmental, susceptible-infectious-susceptible (SIS) model of HPV transmission and disease among GBMSM to estimate changes in HPV, anogenital wart, and HPV-attributable cancer incidence when the upper age for vaccination among GBMSM was raised to age 30, 35, 40, or 45 years. We then estimated changes in quality adjusted life years (QALYs), costs (vaccination costs and direct medical costs of HPV disease), and the incremental cost-effectiveness ratio under each of these scenarios.</div></div><div><h3>Results</h3><div>Our estimates showed that HPV vaccination of GBMSM was cost-saving through age 45 years, i.e., the costs of vaccination are more than offset by decreases in the direct medical costs of HPV disease. Vaccination of GBMSM through at least age 40 years was cost-saving across most sensitivity analyses.</div></div><div><h3>Conclusions</h3><div>Vaccination of GBMSM through age 45 years is likely a cost-saving use of public health resources.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"65 ","pages":"Article 127798"},"PeriodicalIF":4.5,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}